Company: AIP
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001193125-25-091349
Chunk: 28

Company: Arteris, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 28
---
 RELATED PERSONS

We describe below transactions and series of similar transactions, since January 1, 2022, to which we were a party or will be a
party, in which the amount involved exceeded or will exceed the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed years with any of our directors,
executive officers or holders of more than 5% of our common stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest.

Transchip License Agreement

In February
2022, Arteris IP (Hong Kong) Ltd., now Arteris HK Limited, our wholly-owned subsidiary, entered into a Share Purchase and Shareholders Agreement (the “SPA”) with certain investors and Ningbo Transchip Information Consulting Partnership.
The transaction closed on June 20, 2022.

Pursuant to the SPA, we subscribed to the registered capital of Transchip Technology
(Nanjing) Co., Ltd. (“Transchip”), our formerly wholly-owned subsidiary. As a result, the registered capital of Transchip increased to $29.4 million. We subscribed for the registered capital of approximately $11.9 million, of
which $11.6 million of the contribution was contributed in-kind by way of an interconnect solutions and software technology license by us pursuant to a five-year technology license and services agreement
which can be extended automatically for another five-year term, and the remaining was paid in cash. Upon closing of the transaction, Transchip was deconsolidated as our subsidiary.

Following the consummation of the foregoing transactions, we held approximately 40% of the common stock of Transchip on a fully diluted
basis. In September 2022, Transchip completed a second funding with additional investors. We did not provide additional investments in the second funding. As a result, our ownership interest in Transchip was diluted to 35.0% of the common stock of
Transchip on a fully diluted basis.

Director and Executive Officer Compensation

See “Executive Compensation” and “Director Compensation” for information regarding compensation of directors and
executive officers.

Employment Agreements

We have entered into employment agreements with certain of our named executive officers. For more information regarding these agreements,
see “Executive Compensation–Narrative to Summary Compensation Table.”

Director and Officer Indemnification and Insurance

We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among